Related Experiment Video
Updated: Jun 28, 2026
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
[Effect of mycophenolate mofetil on the expression of early inflammatory reaction in diabetic rats]
1Department of Nephrology, Third Xiangya Hospital,Central South University, Changsha 410013, China.
Objective:
To investigate the effect of mycophenolate mofetil(MMF) on early inflammatory reaction of renal lesion in streptozotocin(STZ)-induced diabetic rats.
Methods:
Thirty-six male Sprague-Dawley rats were randomly divided into 3 groups after uninephrectomy: normal control group, diabetic model group, and MMF-treated group. Six rats in each group were sacrificed at the 4th week and 14th week after STZ injection. Twenty-four hour urinary protein (24 h Upro) count was measured before death. The expressions of regulated on activation of normal T expressed and secreted (RANTES),ectodermal dysplasia (ED-1)and Col-IV protein in the renal tissue were detected by immunohistochemistry. The expression of RANTES mRNA in the renal tissue was detected by RT-PCR.
Results:
MMF prevented the increasing of 24h Upro in diabetic rats,and the expressions of RANTES,ED-1,Col-IV protein and RANTES mRNA in the kidney of MMF-treated rats were significantly decreased.
Conclusion:
MMF plays an early renal protective role in diabetic nephropathy, possibly through inhibition of early inflammatory reaction.
Insights
Mycophenolate mofetil (MMF) reduces early kidney damage in diabetic rats by decreasing inflammation markers and protein in urine. This suggests MMF offers early renal protection in diabetic nephropathy.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Diabetic nephropathy is a major complication of diabetes mellitus.
- Early inflammatory responses contribute significantly to renal lesion development in diabetic nephropathy.
Purpose of the Study:
- To evaluate the renoprotective effects of mycophenolate mofetil (MMF) in an early stage of diabetic nephropathy.
- To investigate the impact of MMF on inflammatory markers within the kidney.
Main Methods:
- Streptozotocin (STZ)-induced diabetic rat model with uninephrectomy.
- Treatment groups included normal control, diabetic model, and MMF-treated rats.
- Assessment of 24-hour urinary protein, and immunohistochemical/RT-PCR analysis of renal RANTES, ED-1, Col-IV protein, and RANTES mRNA.
Main Results:
- MMF treatment significantly reduced 24-hour urinary protein levels in diabetic rats.
- MMF administration led to decreased expression of RANTES, ED-1, Col-IV protein, and RANTES mRNA in renal tissue.
- These findings indicate MMF mitigates early inflammatory reactions in the kidney.
Conclusions:
- Mycophenolate mofetil (MMF) demonstrates an early renal protective effect in diabetic nephropathy.
- MMF may exert its protective role by inhibiting early inflammatory processes in the diabetic kidney.
- These results highlight MMF as a potential therapeutic agent for early-stage diabetic kidney disease.
